Free Trial

Akoya Biosciences Q2 2023 Earnings Report

Akoya Biosciences logo
$1.43 -0.06 (-4.03%)
As of 03/28/2025 04:00 PM Eastern

Akoya Biosciences EPS Results

Actual EPS
-$0.51
Consensus EPS
-$0.44
Beat/Miss
Missed by -$0.07
One Year Ago EPS
N/A

Akoya Biosciences Revenue Results

Actual Revenue
$23.52 million
Expected Revenue
$22.17 million
Beat/Miss
Beat by +$1.35 million
YoY Revenue Growth
N/A

Akoya Biosciences Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Remove Ads

Akoya Biosciences Earnings Headlines

Akoya Biosciences downgraded to Equal Weight from Overweight at Stephens
Tikvah intends to vote against Quanterix’s proposed merger with Akoya
Alert: DOGE goes live
Elon will most likely be at the helm of it all. And just days from now, could bring about the biggest economic transformation in American history. See, there's one particular part of Elon and Trump's plans that you need to pay special attention to right now.
See More Akoya Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Akoya Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Akoya Biosciences and other key companies, straight to your email.

About Akoya Biosciences

Akoya Biosciences (NASDAQ:AKYA), a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. It has a collaboration agreement with NeraCare that enables personalized therapy selection for early-stage melanoma patients. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.

View Akoya Biosciences Profile

More Earnings Resources from MarketBeat